A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Clinical trial NCT06545955 · RECRUITING
Trial details
- NCT number
- NCT06545955
- Sponsor
- Ferring Pharmaceuticals
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-10-01
- Primary completion
- 2028-06-30
- Enrollment
- 250
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.